학술논문
The potential of electronic nose technology in lung transplantation: a proof of principle.
Document Type
Academic Journal
Author
Wijbenga N; Dept of Respiratory Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.; Hoek RAS; Dept of Respiratory Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.; Mathot BJ; Dept of Respiratory Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.; Seghers L; Dept of Respiratory Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.; Aerts JGJV; Dept of Respiratory Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.; Manintveld OC; Dept of Cardiology, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.; Hellemons ME; Dept of Respiratory Medicine, Erasmus MC Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
Source
Publisher: European Respiratory Society Country of Publication: England NLM ID: 101671641 Publication Model: eCollection Cited Medium: Print ISSN: 2312-0541 (Print) Linking ISSN: 23120541 NLM ISO Abbreviation: ERJ Open Res Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2312-0541
Abstract
Exhaled breath analysis using eNose technology holds promise as a point-of-care indicator of clinical status after lung transplantation. This case study invites further exploration of eNose technology in the field of lung transplantation. https://bit.ly/3wgQ3DE.
Competing Interests: Conflict of interest: N. Wijbenga has no conflicts of interest to disclose. Conflict of interest: R.A.S. Hoek has no conflicts of interest to disclose. Conflict of interest: B.J. Mathot has no conflicts of interest to disclose. Conflict of interest: L. Seghers has no conflicts of interest to disclose. Conflict of interest: J.G.J.V. Aerts reports personal fees and nonfinancial support from MSD; and personal fees from BMS, Boehringer Ingelheim, Amphera, Eli Lilly, Takeda, Bayer, Roche and Astra Zeneca, outside the submitted work. In addition, he has a patent on allogenic tumour cell lysate licensed to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending. Conflict of interest: O.C. Manintveld has no conflicts of interest to disclose. Conflict of interest: M.E. Hellemons is an associate editor of this journal.
(Copyright ©The authors 2022.)
Competing Interests: Conflict of interest: N. Wijbenga has no conflicts of interest to disclose. Conflict of interest: R.A.S. Hoek has no conflicts of interest to disclose. Conflict of interest: B.J. Mathot has no conflicts of interest to disclose. Conflict of interest: L. Seghers has no conflicts of interest to disclose. Conflict of interest: J.G.J.V. Aerts reports personal fees and nonfinancial support from MSD; and personal fees from BMS, Boehringer Ingelheim, Amphera, Eli Lilly, Takeda, Bayer, Roche and Astra Zeneca, outside the submitted work. In addition, he has a patent on allogenic tumour cell lysate licensed to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending. Conflict of interest: O.C. Manintveld has no conflicts of interest to disclose. Conflict of interest: M.E. Hellemons is an associate editor of this journal.
(Copyright ©The authors 2022.)